QQ客服 官方微博 反馈留言

	Combination of Human Fas (CD95Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response
	Liu, Zhongchen ; Liu, Ruizhen ; Qiu, Jinhua ; Yin, Ping（Zhongshan Hospital, Xiamen University） ; Luo, Fanghong ; Su, Jinhua ; Li, Wenzhu ; Li WZ(李文珠) ; Chen, Caixia ; Chen CX(陈彩霞) ; Fan, Xin ; Zhang, Jiakai ; Zhang JK(张佳锴) ; Zhuang, Guohong
	2009
关键词	hepatocellular carcinoma combination therapy FasL ADM apoptosis
英文摘要	The prognosis of hepatocellular carcinoma (HCC) is poor, even with the combined treatment of curative resection and adjuvant chemoradiotherapy. To solve this problem, many biologic therapies have been investigated. Fas ligand (FasL, CD95L) is mainly expressed in activated T lymphocytes and natural killer (NK) cells, and plays a central role in both cell-mediated immunity and immune downregulation. Several studies have shown that FasL is expressed in HCC. In the present report, we prepared recombinant human pET-22b(+)/FasL protein and investigated the effect of FasL on HCC cells in vitro and on tumor growth in a murine HCC tumor model. The well-known cytotoxic chemotherapeutic reagent adriamycin (ADM) served as a control. We found that FasL effectively suppressed the viability of H22 tumor cells and significantly induced the apoptosis of H22 cells. The apoptotic levels of cells treated with FasL-ADM were significantly higher than those treated with FasL or ADM alone, and the FasL-ADM combination resulted in a more than additive effect on tumor growth delay in this model. The results suggested that combined treatment of FasL and other chemotherapeutic agents may be a new approach to improve the efficacy of chemotherapy for HCC. Cellular & Molecular Immunology. 2009;6(3):167-174.; scientific research foundation of Fujian Province [C0710046]
语种	英语
出版者	CHINESE SOC IMMUNOLOGY
内容类型	期刊论文
源URL	[http://dx.doi.org/doi:10.1038/cmi.2009.23]
专题	生命科学－已发表论文
推荐引用方式 GB/T 7714	Liu, Zhongchen,Liu, Ruizhen,Qiu, Jinhua,et al. Combination of Human Fas (CD95Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response[J],2009.
APA	Liu, Zhongchen.,Liu, Ruizhen.,Qiu, Jinhua.,Yin, Ping.,Luo, Fanghong.,...&Zhuang, Guohong.(2009).Combination of Human Fas (CD95Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response..
MLA	Liu, Zhongchen,et al."Combination of Human Fas (CD95Apo-1) Ligand with Adriamycin Significantly Enhances the Efficacy of Antitumor Response".(2009).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。